KR100914702B1 - 폐렴구균의 캡슐 다당류 생산의 조절 방법 - Google Patents
폐렴구균의 캡슐 다당류 생산의 조절 방법 Download PDFInfo
- Publication number
- KR100914702B1 KR100914702B1 KR1020027012159A KR20027012159A KR100914702B1 KR 100914702 B1 KR100914702 B1 KR 100914702B1 KR 1020027012159 A KR1020027012159 A KR 1020027012159A KR 20027012159 A KR20027012159 A KR 20027012159A KR 100914702 B1 KR100914702 B1 KR 100914702B1
- Authority
- KR
- South Korea
- Prior art keywords
- pneumococcal
- cps
- delete delete
- cpsd
- carbon dioxide
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
균주 | 캡슐화 | 점액상 | 특성/유전자형 | 표현형7 Mab 4G10(+/-) | 참고 문헌 | ||
+/- | 타입 | 호기성 | 혐기성 | ||||
P303 | + | 6A | 없음 | 있음 | 임상적 분리물 | + | Kim 등 1998 |
P324 | + | 6B | 없음 | 있음 | 임상적 분리물 | + | Kim 등 1998 |
P68 | + | 18C | 없음 | 있음 | 임상적 분리물 | + | Kim 등 1998 |
P10 | + | 9V | 없음 | 있음 | 임상적 분리물 | + | Weiser 등 1994 |
D39 | + | 22 | 없음 | 있음 | 임상적 분리물 | + | Avery 등 1944 |
R6x | - | 없음 | 없음 | D39 (Δcps2A-cps2H) | - | Iannelli 등 1999 | |
SIII | + | 3 | 있음 | 있음 | 임상적 분리물 | - | Avery 등 1944 |
P138 | + | 3 | 있음 | 있음 | R6x xSIII DNA | - | Saluja 등 1995 |
P728 | + | 2 | 없음 | 있음 | R6x xD39 DNA | + | 본 실시예 |
7 각각의 균주/변이체의 경우, 산소의 존재하에서 증식된 O 표현형을 테스트하였으며, '+'는 25∼27 kD의 단일 밴드를 갖는 반응성을 나타냄 |
콜로니 표현형 | 환자수 | 타입(번호) | HIV 상태 | |||
비인강 | 혈액/CSF1 | + | - | N/A2 | ||
T | T | 7 | 1(4),4,18,19 | 5 | 1 | 1 |
0 | 0 | 2 | 1(2) | 1 | 0 | 1 |
0 | T | 0 | ||||
T | 0 | 10 | 1(4),4(2),6,12,15,22 | 5 | 1 | 4 |
주: 1 4/19 침입성 분리물은 혈액보다는 뇌척수액으로부터 얻음 2 N/A는 이용이 불가한 임상적 상태를 의미함 |
콜로니 형태3 | ||||||
O형 | T형 | |||||
O2(%) | 21 | 16 | <0.1 | 21 | 16 | <0.1 |
CO2(%) | <0.1 | 3 | 10 | <0.1 | 3 | 10 |
평균 콜로니 면적(㎟)4 | 3.53 | 7.42 | 169 | 1.02 | 5.15 | 12.3 |
캡슐을 포함한 단일 세포 점유 체적 (㎛3)5 | 3.64 | 6.85 | 63.5 | UD | 4.62 | 10.6 |
캡슐 다당류(ng/㎍ 총 단백질)6 | 126 | 221 | 997 | 35.4 | 19.4 | 34.2 |
3 동일한 타입 6A의 임상적 분리물의 O 및 T 변이체에 대한 것임. 4 이들 값은 16 시간 증식 후에 관찰된 콜로니에 기초한 것임. 값은 3개의 단일 웰의 분리된 콜로니를 사용하여 행해진 측정의 평균을 나타냄. 5 이들 값은 팽화반응 및 구형 타원체 체적에 대한 식인 V=(π/6)LW2을 사용하여 밝혀진 캡슐 물질에 기초한 것임. 값은 3개의 쌍구균 형태를 단일 세포에 상응하도록 2개로 나누어 측정한 평균값임. "UD" 는 캡슐 물질의 영역이 검출되지 않음을 의미함. 6 이들 값은 대수기에서 액체 배지 중의 생물체 증식의 포착형 ELISA 평가에 기초한 것임. 값은 2회의 별도의 측정의 평균이다. |
콜로니의 불투명한 표현형 및 산소압에 대한 반응에서 CPS 생산을 조절하는 메카니즘의 다음의 모델이 제안된다. 상기 모델은 cpsD의 전사 조절 및 CpsD의 후전사 변형을 포함한다.
Claims (27)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- a) 폐렴구균의 불투명 변이체를 얻는 단계;b) 산소 농도가 16% 미만인 가스와 접촉하고 있는 증식 배지에서 상기 폐렴구균의 불투명 변이체를 유지하는 단계; 및c) 상기 세포에 의해 생산된 캡슐 다당류를 세포에서 분리하는 단계를 포함하고,상기 분리된 다당류가 면역원성 제제를 구성하는 것을 특징으로 하는폐렴구균 감염이 일어날 위험이 있는 동물에게 투여하기 위한 면역원성 제제의 제조 방법.
- 제11항에 있어서, 상기 가스는 산소 농도가 0.1% 이하인 것을 특징으로 하는 폐렴구균 감염이 일어날 위험이 있는 동물에게 투여하기 위한 면역원성 제제의 제조 방법.
- 제11항에 있어서, 상기 가스는 이산화탄소 농도가 0.04% 초과인 것을 특징으로 하는 폐렴구균 감염이 일어날 위험이 있는 동물에게 투여하기 위한 면역원성 제제의 제조 방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 폐렴구균의 불투명 변이체를 얻는 단계, 및 산소 함량이 16% 미만이고 이산화탄소로 포화된 증식 배지에서 상기 폐렴구균을 유지하는 단계를 포함하는 것을 특징으로 하는 폐렴구균 다당류를 생산하는 방법.
- 제19항에 있어서, 상기 증식 배지는 탄산염 또는 중탄산염을 포함하는 것을 특징으로 하는 폐렴구균 다당류를 생산하는 방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제12항에 있어서, 상기 가스는 이산화탄소 농도가 10% 초과인 것을 특징으로 하는 폐렴구균 감염이 일어날 위험이 있는 동물에게 투여하기 위한 면역원성 제제의 제조 방법.
- 폐렴구균의 불투명 변이체를 얻는 단계, 및 산소 농도가 0.1% 이하이고 이산화탄소 함량이 10% 초과인 증식 배지에서 상기 폐렴구균을 유지하는 단계를 포함하는 것을 특징으로 하는 폐렴구균 다당류를 생산하는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18984700P | 2000-03-16 | 2000-03-16 | |
US60/189,847 | 2000-03-16 | ||
PCT/US2001/008442 WO2001068903A1 (en) | 2000-03-16 | 2001-03-16 | Modulating production of pneumococcal capsular polysaccharide |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087017844A Division KR20080081978A (ko) | 2000-03-16 | 2001-03-16 | 폐렴구균의 캡슐 다당류 생산의 조절 방법 |
KR1020087006798A Division KR100942738B1 (ko) | 2000-03-16 | 2001-03-16 | 폐렴구균의 캡슐 다당류 생산의 조절 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030040196A KR20030040196A (ko) | 2003-05-22 |
KR100914702B1 true KR100914702B1 (ko) | 2009-08-28 |
Family
ID=22699002
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087006798A KR100942738B1 (ko) | 2000-03-16 | 2001-03-16 | 폐렴구균의 캡슐 다당류 생산의 조절 방법 |
KR1020087017844A KR20080081978A (ko) | 2000-03-16 | 2001-03-16 | 폐렴구균의 캡슐 다당류 생산의 조절 방법 |
KR1020027012159A KR100914702B1 (ko) | 2000-03-16 | 2001-03-16 | 폐렴구균의 캡슐 다당류 생산의 조절 방법 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087006798A KR100942738B1 (ko) | 2000-03-16 | 2001-03-16 | 폐렴구균의 캡슐 다당류 생산의 조절 방법 |
KR1020087017844A KR20080081978A (ko) | 2000-03-16 | 2001-03-16 | 폐렴구균의 캡슐 다당류 생산의 조절 방법 |
Country Status (19)
Country | Link |
---|---|
US (1) | US6642017B2 (ko) |
EP (2) | EP1268844B1 (ko) |
JP (1) | JP4856345B2 (ko) |
KR (3) | KR100942738B1 (ko) |
CN (2) | CN101586143A (ko) |
AT (1) | ATE437955T1 (ko) |
AU (2) | AU2001245795B2 (ko) |
BR (1) | BRPI0109293B8 (ko) |
CA (1) | CA2403001C (ko) |
CY (1) | CY1109418T1 (ko) |
DE (1) | DE60139384D1 (ko) |
DK (1) | DK1268844T3 (ko) |
ES (1) | ES2330919T3 (ko) |
HK (1) | HK1055448A1 (ko) |
IL (3) | IL151772A0 (ko) |
MX (1) | MXPA02009047A (ko) |
NZ (1) | NZ521343A (ko) |
PT (1) | PT1268844E (ko) |
WO (1) | WO2001068903A1 (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4856345B2 (ja) * | 2000-03-16 | 2012-01-18 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ニューモコッカス莢膜多糖類の調整的製造 |
EP3466982B1 (en) * | 2005-04-08 | 2020-06-17 | Wyeth LLC | Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation |
US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7491517B2 (en) * | 2006-07-19 | 2009-02-17 | Jeeri R Reddy | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 |
RU2460539C2 (ru) * | 2006-10-10 | 2012-09-10 | Вайет | СПОСОБ ОЧИСТКИ ПОЛИСАХАРИДОВ Streptococcus pneumoniae 3 ТИПА (ВАРИАНТЫ) |
WO2009059054A2 (en) * | 2007-10-30 | 2009-05-07 | The Trustees Of The University Of Pennsylvania | Bacteria strains an d bacteriocin produced therefrom |
PT2385981T (pt) * | 2008-12-18 | 2019-10-28 | Wyeth Llc | Método para controlar peso molecular de polissacárido de streptococcus pneumoniae com a utilização de carbono. |
WO2010080486A2 (en) | 2008-12-18 | 2010-07-15 | Wyeth Llc | Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight |
CN102093963B (zh) * | 2010-11-26 | 2012-11-14 | 兰州生物制品研究所有限责任公司 | 富含磷壁酸的肺炎链球菌的培养方法 |
US10150979B2 (en) | 2014-05-07 | 2018-12-11 | Glaxosmithkline Biologicals Sa | Purification of secreted polysaccharides from S. agalactiae |
US10611664B2 (en) | 2014-07-31 | 2020-04-07 | Corning Incorporated | Thermally strengthened architectural glass and related systems and methods |
EP3174835A1 (en) | 2014-07-31 | 2017-06-07 | Corning Incorporated | Thermally tempered glass and methods and apparatuses for thermal tempering of glass |
US11097974B2 (en) | 2014-07-31 | 2021-08-24 | Corning Incorporated | Thermally strengthened consumer electronic glass and related systems and methods |
WO2017123573A2 (en) | 2016-01-12 | 2017-07-20 | Corning Incorporated | Thin thermally and chemically strengthened glass-based articles |
US11795102B2 (en) | 2016-01-26 | 2023-10-24 | Corning Incorporated | Non-contact coated glass and related coating system and method |
US11485673B2 (en) | 2017-08-24 | 2022-11-01 | Corning Incorporated | Glasses with improved tempering capabilities |
TWI785156B (zh) | 2017-11-30 | 2022-12-01 | 美商康寧公司 | 具有高熱膨脹係數及對於熱回火之優先破裂行為的非離子交換玻璃 |
US20210062138A1 (en) * | 2018-01-22 | 2021-03-04 | The Research Foundation For Microbial Diseases Of Osaka University | Medium for culturing pneumococcal samples |
CN116811379A (zh) | 2019-08-06 | 2023-09-29 | 康宁股份有限公司 | 具有用于阻止裂纹的埋入式应力尖峰的玻璃层压体及其制造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2510606A1 (fr) * | 1981-07-30 | 1983-02-04 | Berri Balzac | Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins |
CA2116261A1 (en) * | 1993-04-20 | 1994-10-21 | David E. Briles | Epitopic regions of pneumococcal surface protein a |
WO1995031548A1 (en) * | 1994-05-16 | 1995-11-23 | The Uab Research Foundation | Streptococcus pneumoniae capsular polysaccharide genes and flanking regions |
JP4856345B2 (ja) * | 2000-03-16 | 2012-01-18 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ニューモコッカス莢膜多糖類の調整的製造 |
-
2001
- 2001-03-16 JP JP2001567384A patent/JP4856345B2/ja not_active Expired - Lifetime
- 2001-03-16 US US09/831,184 patent/US6642017B2/en not_active Expired - Lifetime
- 2001-03-16 EP EP01918754A patent/EP1268844B1/en not_active Expired - Lifetime
- 2001-03-16 NZ NZ521343A patent/NZ521343A/en not_active IP Right Cessation
- 2001-03-16 EP EP08011745A patent/EP1967591A3/en not_active Withdrawn
- 2001-03-16 KR KR1020087006798A patent/KR100942738B1/ko active IP Right Grant
- 2001-03-16 DE DE60139384T patent/DE60139384D1/de not_active Expired - Lifetime
- 2001-03-16 IL IL15177201A patent/IL151772A0/xx unknown
- 2001-03-16 CN CNA200910150337XA patent/CN101586143A/zh active Pending
- 2001-03-16 CA CA2403001A patent/CA2403001C/en not_active Expired - Lifetime
- 2001-03-16 AU AU2001245795A patent/AU2001245795B2/en not_active Expired
- 2001-03-16 BR BRPI0109293A patent/BRPI0109293B8/pt not_active IP Right Cessation
- 2001-03-16 KR KR1020087017844A patent/KR20080081978A/ko not_active Application Discontinuation
- 2001-03-16 DK DK01918754T patent/DK1268844T3/da active
- 2001-03-16 AT AT01918754T patent/ATE437955T1/de active
- 2001-03-16 PT PT01918754T patent/PT1268844E/pt unknown
- 2001-03-16 CN CNB018096549A patent/CN100529054C/zh not_active Expired - Lifetime
- 2001-03-16 ES ES01918754T patent/ES2330919T3/es not_active Expired - Lifetime
- 2001-03-16 AU AU4579501A patent/AU4579501A/xx active Pending
- 2001-03-16 MX MXPA02009047A patent/MXPA02009047A/es active IP Right Grant
- 2001-03-16 WO PCT/US2001/008442 patent/WO2001068903A1/en active IP Right Grant
- 2001-03-16 KR KR1020027012159A patent/KR100914702B1/ko active IP Right Grant
-
2002
- 2002-09-15 IL IL151772A patent/IL151772A/en active IP Right Grant
-
2003
- 2003-10-29 HK HK03107802.0A patent/HK1055448A1/xx unknown
-
2008
- 2008-06-05 IL IL191962A patent/IL191962A/en active IP Right Grant
-
2009
- 2009-09-28 CY CY20091101008T patent/CY1109418T1/el unknown
Non-Patent Citations (3)
Title |
---|
Epidemiol. Infect., Vol.117(3), Abstract(1996)* |
J. Clin. Path., Vol.29, pp.50-53(1976)* |
J. Clin. Pathol., Vol.40(4), pp.368-371(1987)* |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100914702B1 (ko) | 폐렴구균의 캡슐 다당류 생산의 조절 방법 | |
Luck et al. | Sugar-coated killer: serotype 3 pneumococcal disease | |
Hammerschmidt et al. | Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells | |
Weiser et al. | Changes in availability of oxygen accentuate differences in capsular polysaccharide expression by phenotypic variants and clinical isolates of Streptococcus pneumoniae | |
Kwara et al. | Meningitis caused by a serogroup W135 clone of the ET‐37 complex of Neisseria meningitidis in West Africa | |
AU2001245795A1 (en) | Modulating production of pneumococcal capsular polysaccharide | |
Lizcano et al. | Transcriptional organization of pneumococcal psrP-secY2A2 and impact of GtfA and GtfB deletion on PsrP-associated virulence properties | |
US5871951A (en) | Compositions and methods for treatment of infection caused by Haemophilus influenzae and Streptococcus pneumoniae | |
Reeks et al. | Effects of sub-minimum inhibitory concentration antibiotic levels and temperature on growth kinetics and outer membrane protein expression in Mannheimia haemolytica and Haemophilus somnus | |
WO1998012346A9 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF INFECTION CAUSED BY HAEMOPHILUS INFLUENZAE AND $i(STREPTOCOCCUS PNEUMONIAE) | |
Nomura et al. | Contribution of glucan-binding protein C of Streptococcus mutans to bacteremia occurrence | |
US7189554B2 (en) | Two-component system that controls bacterial membrane synthesis | |
EA014065B1 (ru) | Средство, обладающее свойством формировать клеточный иммунитет против mycobacterium tuberculosis h37 rv, способ получения его (варианты), рекомбинантный штамм и средство для диагностики туберкулеза | |
JP4819504B2 (ja) | 新規血清型のストレプトコッカスミュータンスおよびその利用 | |
Teodoro | Pneumococcal invasive disease in adults (2015-2017): epidemiological and molecular characterization of Streptococcus pneumoniae and genomic analysis of emerging clones | |
AL-Saad | Study of Some Virulence Factor and Detection of Sortase Enzymes A and Cov R/S of Streptococcus Agalactiae by PCR | |
Paton et al. | Streptococcus pneumoniae capsular polysaccharide | |
Spencer | O-Acetyltransferase Functionality Mediates Pneumococcal Capsular Diversity | |
Kasper et al. | Development of Vaccines to Prevent Wound Infections due to Anaerobic Bacteria | |
test Pharyngitis et al. | In the last two decades, DNA homology and DNA | |
during Adherence | Illustration of Pneumococcal | |
Lacoux | A study of the typing of the genus Enterococcus | |
Semchenko | Characterisation of Campylobacter jejuni Lipooligosaccharides | |
Brugger | Interactions of" Streptococcus Pneumoniae" with the Human Nasopharynx | |
Bender | Modulation of Streptococcus pneumoniae capsule production by autophosphorylating tyrosine kinase activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E902 | Notification of reason for refusal | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120731 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130827 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140819 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150729 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160727 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170804 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180730 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190729 Year of fee payment: 11 |